Cargando…
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
Treatment of patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma remains an unmet clinical need, and the progressive myocardial toxicity related to cumulative, dose-dependent damage induced by anthracyclines represents a tricky issue in the planning of therapy. Pixantrone is...
Autores principales: | Volpetti, Stefano, Zaja, Francesco, Fanin, Renato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049882/ https://www.ncbi.nlm.nih.gov/pubmed/24926199 http://dx.doi.org/10.2147/OTT.S34055 |
Ejemplares similares
-
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial
por: Pettengell, Ruth, et al.
Publicado: (2016) -
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković, Barbara, et al.
Publicado: (2021) -
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial
por: Pettengell, Ruth, et al.
Publicado: (2018) -
Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
por: Novakovic, Aleksander, et al.
Publicado: (2020) -
Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
por: Lucchini, Elisa, et al.
Publicado: (2021)